Literature DB >> 15471990

Bacteriolytic therapy can generate a potent immune response against experimental tumors.

Nishant Agrawal1, Chetan Bettegowda, Ian Cheong, Jean-Francois Geschwind, Charles G Drake, Edward L Hipkiss, Mitsuaki Tatsumi, Long H Dang, Luis A Diaz, Martin Pomper, Mohammad Abusedera, Richard L Wahl, Kenneth W Kinzler, Shibin Zhou, David L Huso, Bert Vogelstein.   

Abstract

When spores of the anaerobic bacterium Clostridium novyi-NT are systemically injected into animals, they germinate exclusively within the hypoxic regions of cancers. The germinated bacteria destroy adjacent tumor cells but spare a rim of well oxygenated tumor cells that subsequently expand. Surprisingly, we found that approximately 30% of mice treated with such spores were cured of their cancers despite the viable tumor rim initially remaining after spore germination. The mechanism underlying this effect was shown to be immune-mediated, because cured animals rejected a subsequent challenge of the same tumor. Similar effects were observed in rabbits with intrahepatic tumors. It was particularly notable that the induced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate large established tumors.

Entities:  

Mesh:

Year:  2004        PMID: 15471990      PMCID: PMC523456          DOI: 10.1073/pnas.0406242101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Cancer Vaccine Collaborative 2002: opening address.

Authors:  Lloyd J Old
Journal:  Cancer Immun       Date:  2003-02-06

3.  Lethal outbreak of infection with Clostridium novyi type A and other spore-forming organisms in Scottish injecting drug users.

Authors:  Christopher C McGUIGAN; Gillian M Penrice; Laurence Gruer; Syed Ahmed; David Goldberg; Marjorie Black; Jane E Salmon; John Hood
Journal:  J Med Microbiol       Date:  2002-11       Impact factor: 2.472

Review 4.  Points of control in inflammation.

Authors:  Carl Nathan
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 5.  Tumor angiogenesis: past, present and the near future.

Authors:  R S Kerbel
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

6.  Combination bacteriolytic therapy for the treatment of experimental tumors.

Authors:  L H Dang; C Bettegowda; D L Huso; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

7.  Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis.

Authors:  T K Means; S Wang; E Lien; A Yoshimura; D T Golenbock; M J Fenton
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

Review 8.  Tumor immunology--towards a paradigm of reciprocal research.

Authors:  Charles G Drake; Drew M Pardoll
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

9.  Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.

Authors:  S C Liu; N P Minton; A J Giaccia; J M Brown
Journal:  Gene Ther       Date:  2002-02       Impact factor: 5.250

Review 10.  Tumor-specific shared antigenic peptides recognized by human T cells.

Authors:  Pierre Van Der Bruggen; Yi Zhang; Pascal Chaux; Vincent Stroobant; Christophe Panichelli; Erwin S Schultz; Jacques Chapiro; Benoît J Van Den Eynde; Francis Brasseur; Thierry Boon
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

View more
  87 in total

1.  Synthetic biology for translational research.

Authors:  Peter D Burbelo; Kathryn H Ching; Brian L Han; Caitlin M Klimavicz; Michael J Iadarola
Journal:  Am J Transl Res       Date:  2010-07-20       Impact factor: 4.060

2.  Structural characterization of the polar lipids of Clostridium novyi NT. Further evidence for a novel anaerobic biosynthetic pathway to plasmalogens.

Authors:  Ziqiang Guan; Norah C Johnston; Semra Aygun-Sunar; Fevzi Daldal; Christian R H Raetz; Howard Goldfine
Journal:  Biochim Biophys Acta       Date:  2010-12-30

3.  A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy.

Authors:  Kelly Flentie; Brandon Kocher; Seth T Gammon; Deborah V Novack; Jeffrey S McKinney; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

4.  Tumor Microenvironment Targeting Nano-Bio Emulsion for Synergistic Combinational X-Ray PDT with Oncolytic Bacteria Therapy.

Authors:  Wooram Park; Soojeong Cho; Dongkyu Kang; Jun-Hyeok Han; Jung-Hoon Park; Byeongdu Lee; Joonseok Lee; Dong-Hyun Kim
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

Review 5.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 6.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

7.  Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI.

Authors:  Guanshu Liu; Chetan Bettegowda; Yuan Qiao; Verena Staedtke; Kannie W Y Chan; Renyuan Bai; Yuguo Li; Gregory J Riggins; Kenneth W Kinzler; Jeff W M Bulte; Michael T McMahon; Assaf A Gilad; Bert Vogelstein; Shibin Zhou; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2013-10-07       Impact factor: 4.668

Review 8.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

9.  Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy.

Authors:  Sheng-Nan Jiang; Thuy X Phan; Taek-Keun Nam; Vu H Nguyen; Hyung-Seok Kim; Hee-Seung Bom; Hyon E Choy; Yeongjin Hong; Jung-Joon Min
Journal:  Mol Ther       Date:  2010-01-05       Impact factor: 11.454

10.  Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Authors:  Shie-Chau Liu; G-One Ahn; Mitomu Kioi; Mary-Jo Dorie; Adam V Patterson; J Martin Brown
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.